What is Anika Therapeutics's EPS (basic)?

Anika Therapeutics (ANIK) reported EPS (basic) of $0.25 in Q2 2026.

What does EPS (basic) mean?

Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.

Anika Therapeutics ANIK EPS (Basic)

EPS (Basic) at other companies

StrykerSYK

$1.95+14.0%

VericelVCEL

-$0.12+47.8%

Zimmer Biomet HoldingsZBH

$1.22+32.6%

Pacira BioSciences, Inc.PCRX

$0.07-30.0%

BioventusBVS

$0.05+225%

Xtant Medical HoldingsXTNT

-$0.02—

Other financials

Income statement

See full

Revenue$32.6M+15.6%

Net income$3.3M+183%

EPS (diluted)$0.24—

Balance sheet

See full

Cash & equivalents$38.4M-27.8%

Total debt$25.7M+1.2%

Total equity$137.3M-7.0%

Total assets$183.5M-2.2%

Cash flow

See full

Operating cash flow-$684.0K-262%

CapEx$1.4M-1.2%

Free cash flow-$2.1M-28.8%

Valuation

See full

Market cap$199.85M+23.0%

P/S1.7×-0.1×

Profitability

See full

Net margin-3.4%-1.6pp

FCF margin0.5%—

Returns & leverage

See full

Return on equity-2.9%-1.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.7×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Anika Therapeutics’s 8-K, filed July 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Anika Therapeutics's EPS (basic)?: Anika Therapeutics (ANIK) reported EPS (basic) of $0.25 in Q2 2026.
What does EPS (basic) mean?: Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.